Evidence suggests commercial health plans are more likely to delay specialty drug coverage decisions in response to FDA ...
New data found Pegylated Interferon-lambda (PegIFN-lambda) shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon ...
Evidence suggests commercial health plans are more likely to delay specialty drug coverage decisions in response to FDA label expansions vs contractions. “The Timeliness of Health Plan Drug Coverage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results